From The Motley Fool · The Motley Fool Team · · 40s
Danaher Boosts Long-Term Growth Outlook
Danaher's earnings beat signals stronger bioprocessing and diagnostics demand for long-term investors.
In brief
Danaher's earnings beat signals stronger bioprocessing and diagnostics demand for long-term investors. Danaher raised full-year EPS guidance after accelerating bioprocessing orders and strategic acquisitions to drive long-term growth. Originally reported by The Motley Fool.
Earnings Guidance Raised
Danaher raised full-year EPS guidance following higher third-quarter core revenue growth.
“For long-term investors, the performance signals accelerating demand across core bioprocessing and clinical diagnostic markets”
Shift to Organic Growth
Management shifts focus from portfolio restructuring to selling more effectively across operating units.
“With that portfolio transformation largely complete, our focus is shifting from reshaping the portfolio to delivering more growth from the businesses we own”
Bioprocessing Orders Accelerate
Biomanufacturing customers expand production as new therapies advance, driving higher demand for upstream consumables.
“Orders grew mid-teens in the quarter, with particular strength in both upstream consumables as well as reagents”
Strategic Acquisitions Prioritized
Management maintains mergers and acquisitions as primary tool to deploy capital and compound long-term returns.
“We will maintain the robust investment criteria that has served us well for many decades while bringing strategic clarity and discipline to how we allocate capital and resources”
The takeaway
Danaher raised full-year EPS guidance after accelerating bioprocessing orders and strategic acquisitions to drive long-term growth.
